Elicera Therapeutics AB (publ)
Stockholm Stock Exchange ELIC.ST
Elicera Therapeutics AB (publ) Net Income for the year ending December 31, 2023: USD -1.62 M
-
Elicera Therapeutics AB (publ) Net Income for the year ending December 31, 2022 was USD -1.86 M, a -29.00% change year over year.
-
Elicera Therapeutics AB (publ) Net Income for the year ending December 31, 2021 was USD -1.44 M, a -323.03% change year over year.
-
Elicera Therapeutics AB (publ) Net Income for the year ending December 31, 2020 was USD -341.51 K, a -1,608.39% change year over year.
-
Elicera Therapeutics AB (publ) Net Income for the year ending December 31, 2019 was USD -19.99 K.
| Date | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) | Net Income Margin |
|---|
Don’t Miss A Beat
| CEO | Mr. Jamal El-Mosleh M.Sc. |
| IPO Date | June 11, 2021 |
| Location | Sweden |
| Headquarters | World Trade Center GOeteborg |
| Employees | 2 |
| Sector | Healthcare |
| Industries | |
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.
Past 5 years
USD 0.21
StockViz Staff
February 4, 2025
Any question? Send us an email